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Abstract
OBJECTIVE: To evaluated the effect of calycosin on
left ventricular ejection fraction and angiogenesis.
METHODS: Adult male Sprague-Dawley rats were
randomly assigned into calycosin-treated groups
(0.5, 1, 2, and 4 mg/kg qd), a dimethyl sulfoxide
(DMSO), or a sham-operated control group. The
myocardial ischaemia (MI) model was intraperitone-
ally administered calycosin for 28 days. The survival
rates and left ventricular ejection fractions (LVEF)
were compared between groups. The expression
levels of vascular endothelial growth factor (VEGF)
and cluster of differentiation 31 (CD31) in isch-
aemic myocardium were also measured and com-
pared.
RESULTS: The construction of MI model resulted in
a LVEF reduction of 50% compared with the
sham-control. After 28 days, the LVEF value was
10% higher when calycosin (4 mg/kg) was adminis-
tered compared with the DMSO group. The expres-
sion of VEGF and CD31 showed a dose-dependent
manner when calycosin was administrated. The ca-
lycosin-treated (4 mg/kg) group displayed a two-
fold increase in VEGF expression at both the mRNA
and protein levels compared with the DMSO group.
In addition, CD31 expression in the microvascular
increased 1.5-fold in the 4 mg/kg calycosin-treated
group.
CONCLUSION: Calycosin improved left ventricular
ejection fraction in the MI rat models, induced
VEGF expression in the ischaemic myocardium, in-
creased CD31 expression and promoted angiogen-
esis.
© 2015 JTCM. All rights reserved.
Key words: Stroke volume; Angiogenesis inducing
agents; Vascular endothelial growth factor A; Anti-
gens, CD31; 7,3'-dihydroxy-4'-methoxyisoflavone
INTRODUCTION
Cardiovascular diseases (CVDs) is the leading cause of
death worldwide. In 2011, approximately 230 million
people were affected by CVD in China. Moreover, it is
estimated that 9590 people die each day in China due
to the diseases.1 Myocardial ischaemia (MI) is one of
the most common CVDs.2 Myocardial ischaemia reper-
fusion (MIR) is recognized as one of the most suitble
methods for MI treatment.3 Studies indicate that this
treatment leads to recanalisation, an increased survival
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rate and improved left ventricular function.4 Among
several MIR methods, percutaneous coronary interven-
tion (PCI) is recognized to be one of the fastest and
most direct ways to save the sufferers from myocardi-
um. Unfortunately, this method inherits unpredictable
risks to cardiac function and, in some cases, even
death, possibly because of the damage to the myocardi-
um due to the infarcted vascular. Thus, promoting an-
giogenesis after MI is not only important to patients'
recovery but is also crucial to the success of direct
PCI.5 Researchers have attempted to regenerate dam-
aged myocardium by combining thrombolytic therapy,
direct PCI and stem cell treatment together; however,
the results have not been promising.3,6,7 Thus, the res-
cue of impaired myocardium after surgery is still one
obstacle in MI treatments, and promoting angiogenesis
activity in MI patients remains an essential task for a
successful treatment.
Calycosin is the major isoflavonoid in Huangqi (Radix
Astragali Mongolici), synonyms: Astragalus membrana-
ceus (Fisch.) Bunge and Astragalus membranaceus
(Fisch.) Bunge var. mongholicus), a traditional Chinese
herbal medicine, and is proven to promote the prolifer-
ation of the endodermis and angiogenesis.8) This isofla-
vonoid is proposed to be a new alternative drug for the
treatment of cardiovascular diseases.8,9 Calycosin exhib-
its similar effects as estrogen receptor modulators
(SERMs) in zebrafish and human umbilical vein endo-
thelial cells (HUVEC), which activate the MAPK sig-
naling pathway and up-regulate vascular endothelial
growth factor (VEGF).9 The up-regulation of VEGF
expression is closely related to angiogenesis,10 which
partially explains the mechanism of calycosin's effects
in promoting endodermis proliferation. Although a
mechanism for improving angiogenesis by using calyco-
sin has been proposed, a detailed study involving an an-
imal MI model is still required to demonstrate its clini-
cal application potential further.
To demonstrate angiogenesis at the cellular level, clus-
ter of differentiation 31 (CD31), also known as plate-
let endothelial cell adhesion molecule (PECAM)-1,
was used in an immunohistochemical analysis. CD31
is a surface protein belonging to the immunoglobulin
superfamily. This protein is involved in adhesion/signal-
ing events and is expressed on the cell surface of endo-
thelial cells (ECs).11 CD31 is a well-known marker for
ECs with vessel-forming activity because cells express-
ing the CD31 antigen exhibit increased endothelial re-
pairing and revascularisation activities compared to
CD31- cells. Thus, an increased number of CD31 +
cells indicates a higher level of angiogenesis.12
This study aims to verify the potential of calycosin for
treating MI. Left coronary artery ligation was used to
construct rat MI models,13,14 and the effects of calycosin
on cardiac function were tested. VEGF and CD31 ex-
pression levels in the surviving myocardium were ana-
lyzed to elucidate further its mechanism in promoting
angiogenesis in the models.
MATERIALS ANDMETHODS
Animals
The study was approved by the Animal Ethics Com-
mittee of Shanghai University of Traditional Chinese
Medicine. Seventy-two clean-grade male Sprague-Daw-
ley rats of 6 weeks old weighing (220 ± 20) g, were
used in the following experiments (Shanghai Songlian
Experimental Animal Centre, approval number: SCXK
Hu 2008-0016).
Apparatus and chemicals
Calycosin (purity > 98%, verified by high performance
liquid chromatography; purchased from Sigma-Aldrich
Co., St Louis, MO, USA) was dissolved in dimethyl
sulphoxide (DMSO, from Sigma-Aldrich Co., St Lou-
is, MO, USA) to make a 100 mM stock solution and
stored at 4 ℃ until use. Huangqi (Radix Astragali Mon-
golici) used in this study was from the dried root of As-
tragalus propinquus. Pentobarbital, penicillin and hepa-
rin (150 U) were purchased from Sigma-Aldrich (St
Louis, MO, USA).
Animal echocardiography (Visualsonics, Toronto, On-
tario, Canada) was used to assay the elution fractions.
An animal physiological recorder (Chengdu instru-
ment factory, Chengdu, China) was used in the intra-
operative myocardial infarction model along with an
electrocardiograph (ECG). A spectrophotometer bio-
photometer (Eppendorf, Hamburg, Germany), low-
speed centrifuge 5702 (Eppendorf, Hamburg, Germa-
ny) and high-speed centrifuge 5804R (Eppendorf,
Hamburg, Germany) were used in sample preparation.
An RNA extraction kit (Omega, Doraville, CA, USA)
was used to extract the total RNA. A murine an-
ti-VEGF monoclonal antibody (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA) and fluorescence micro-
scope (CKX41; Olympus, Tokyo, Japan) were used in
the western blotting assay. A mouse anti-CD31 mono-
clonal antibody [mouse monoclonal（LCI-9）to CD31,
Abcam, Cambridge, MA, USA], immunohistochemi-
cal washing buffer (Beyotime, Jiangsu, China), and im-
munohistochemical sealing buffer (Beyotime, Jiangsu,
China) were used in immunohistochemical analysis.
Grouping and treatment
Seventy-two rats were randomly distributed into four
calycosin-treated groups (0.5, 1, 2 and 4 mg/kg of caly-
cosin were intraperitoneally injected after the construc-
tion of the model, n = 48), one DMSO group (vehicle
control group) (DMSO was intraperitoneally injected
after the construction of the model, n = 12) and one
sham-operated control group (thorax was opened and
closed without operation, n = 12). To ensure the absor-
bance of the calycosin in the rats, an intraperitoneal
dose method was used. Calycosin was intraperitoneally
injected after the construction of the model. The rats
were intervened by the daily administration of calyco-
sin for 28 days after the construction of the model.
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Establishment of rat MI models
The rats were acclimated for one week and randomly
assigned into each group. Before starting the surgery,
the rats were anaesthetised by the intraperitoneal injec-
tion of 2.5% pentobarbital at a dose of 0.2 mL/100 g.
For the calycosin-treated and DMSO groups, the heart
was exposed via left thoracotomy at the fourth rib. The
left anterior descending (LAD) artery was then perma-
nently ligated. In the sham control group, the chest
was opened after the LAD artery was located, and
thread was then passed below the LAD artery without
ligation. The chest was subsequently closed. Penicillin
od 150 000 units was intramuscularly given to each rat
for 3 days to prevent infection.
Left ventricular ejection fraction and Myocardial
infarction size
The rats were anesthetized by intraperitoneal injection
2.5% pentobarbital at a dose of 0.2 mL/100 g and
echocardiography was used at a frequency of 17.5 MHz
to assay the left ventricular ejection fraction (LVEF).
The following formula was used to calculate the LVEF:
LVEF = (LVDd3-LVDs3)/LVDd3, where LVDd is the
left ventricular end-diastolic diameter, and LVDs is the
left ventricular end-systolic diameter. The values for
the 48th h and 28th day were calculated and compared
in all groups.
The rats were anesthetized through the intraperitoneal
injection of 2.5% pentobarbital and heparin (150 U)
on the 28th day, and the hearts were then rapidly re-
moved from each animal within the group. The white
area of the myocardia was isolated, dried on
pre-weighed filter paper and weighed. The weights of
the necrotic myocardium for all 6 groups were ana-
lyzed and compared.
RNA extraction and real-time polymerase chain
reaction (PCR)
The hearts extracted above were further utilised here.
The surviving myocardium at the border of the infarc-
tion area was removed, and its total RNA was extract-
ed using a RNA extraction kit according to the manu-
facturer's instructions. The primers for the real-time
PCR of the mouse VEGF gene were designed by the
Shanghai Bole biotechnology company: forward:
5¢-TGTACCTCCACCATGCCAAGT-3¢, and re-
verse: 5¢-TGGAAGATGTCCACCAGGGT-3¢. The
reverse transcription was performed using a kit (Toyo-
bo, Osaka, Japan), and the real-time PCR involved a
3-step method using β-actin as a housekeeping gene.
The expression levels of the VEGF mRNA in all 6
groups were analyzed and compared.
Western blotting assay
The rats' hearts were extracted on the 28th day, and
the surviving myocardium at the border of the infarc-
tion area was removed. Total extracts were prepared in
ice-cold lysis buffer. The lysates were centrifuged at
12 000 ×g for 10 min (4 ℃). The total protein concen-
trations of the supernatants were determined using the
Bradford method and bovine serum albumin as a stan-
dard. SDS-PAGE electrophoresis, blotting and the anti-
body reaction (mouse anti-VEGF, Santa Cruz Biotech-
nology, Santa Cruz, CA, USA) were performed accord-
ing to standard procedures and instructions. The che-
miluminescent method was used for the detection and
analysis. The VEGF expression results shown were nor-
malized to the expression of β-actin.
Immunohistochemistry
The surviving cardiac muscle at the border of the in-
farction area of the extracted rat's heart was removed
and sliced into 8 mm sections for immunohistochemis-
try. The sample was dyed in diluted CD31 (1∶500),
and standard immunohistochemical methods were em-
ployed. The CD31-dyed microvasculature was detect-
ed and counted under a microscope (400 foldsmagnifi-
cation).
Statistical analysis
The SPSS 17.0 (Chicago, IL, USA) was used to pro-
cess tdata. Quantitative values are shown as the mean ±
standard deviation ( xˉ ± s ). Analysis of variancewas
performed and followed by Dunnett's post hoc test.
P < 0.05 was the significant level.
RESULTS
Establishment of the rat MI model
The details of the MI model construction are described
in the Materials and Methods section. Of the prelimi-
nary experiments, 0.5 to 4 mg/kg of calycosin led to an
angiogenic effect in the rat femoral artery ligation mod-
el (data not shown). Therefore, the same dosage range
was used in the following experiments. After 48 h of
surgery, two, three, two, three, two and two of the rats
perished in the 0.5, 1, 2 and 4 mg/kg calycosin-treat-
ed, DMSO and control groups, respectively. The sur-
vival rates at 48 h were: 83.3, 75, 83.3, 75, 83.3 and
83.3%, respectively. The fatalities were predominantly
caused by operational reasons, such as infection or
pneumothorax. The average survival rate was 80.5% at
48 h. After 48 h, all of the remaining rats survived. ST
segment elevation was observed in all the rats in the
model groups by intraoperative monitoring on ECG,
indicating the successful ligation of the LAD artery.
No ST change was observed in the sham control
group. In the model groups, there was no statistically
significant difference in the size of the myocardial in-
farction area. The weights of the myocardial infarction
areas were (0.174 ± 0.029), (0.171 ± 0.025), (0.169 ±
0.025), (0172 ± 0.023) and (0.169 ± 0.033) g for the 4
calycosin-treated (0.5, 1, 2 and 4 mg/kg of calycosin)
and DMSO groups, respectively (Figure 1). These re-
sults indicate the successful construction of a MI mod-
el using rats, and this model was further used to evalu-
ate the effects of calycosin.
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Effect of calycosin on left ventricular ejection fraction
To elucidate the effects of calycosin on cardiac func-
tion in MI, echocardiography was used to assay the
LVEF after 48 h in all six groups. Due to the MI,
LVEF decreased significantly in the calycosin-treated
and DMSO groups (Figure 1). During the first 48 h,
more than 60% of the cardiac function was lost in all
of the LAD artery ligated groups.
On the 28th day, LVEF was again assayed and calculat-
ed. Promisingly, cardiac function was improved, com-
pared with the DMSO group, by treating the rats with
4 mg/kg of calycosin (P = 0.0419, Figure 2). Although
a decrease in LVEF was observed in all groups, the re-
duction levels were relatively smaller for the calycosin-
treated groups compared with the DMSO group (Fig-
ure 3). With the highest calycosin dose (4 mg/kg), the
LVEF decreased by only 1.01% ± 0.71% , which was
significantly lower compared to the DMSO group,
which the LVEF decreased by more than 34% (P=
0.004).
Our results indicate that the effect of calycosin is
dose-dependent and that the administration of a 4 mg/
kg dose is efficacious in improving cardiac function in
our MI model.
Effect of cal]ycosin on VEGF expression
Because angiogenesis is mediated by VEGF up-regula-
tion, the expression level of VEGF was further assayed
in the infarction-influenced myocardium. The surviv-
ing myocardium at the border of the infarction area
was removed from the rats' hearts on the 28th day, and
its total RNA was extracted. A 3-step method was used
along with real-time PCR to analyze the different ex-
pression levels of VEGF mRNA for each group. As
shown in Figure 3, compared with the sham control
group, VEGF expression was increased in the DMSO
group, indicating the self-rescue of the myocardium in
response to MI. As expected, even higher expression
levels of VEGF were observed in the calycosin-treated
groups (Figure 4). Thus, it is clear that the administra-
tion of calycosin enhanced the angiogenesis signal.
Consistent with the improvement in cardiac function,
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Figure 1 LVEF in calycosin, DMSO and sham-control groups at 48th h and 28th day
A-D: treated with 4, 2, 1 and 0.5 mg/kg of calycosin, respectively; E: treated with DMSO; F: sham-control. Four different doses of ca-
lycosin were intraperitoneally injected after the construction of the myocardial ischaemia model. LVEF: left ventricular ejection
fractions; DMSO: dimethyl sulfoxide. The rats were intervened by the daily administration of calycosin for 28 days after the con-
struction of the model. Data were expressed as mean ± standard deviation (n = 9). Difference with aP < 0.05 was considered as sta-
tistically significant and were indicated with an asterisk.
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Figure 2Weight of the infarcted area in model groups
A-D: treated with 4, 2, 1 and 0.5 mg/kg of calycosin, respectively; E: treated with DMSO. DMSO: dimethyl sulfoxide. Data were ex-
pressed as mean ± standard deviation (n = 9 ). Four different doses of calycosin were intraperitoneally injected after the construc-
tion of the myocardial ischaemiamodel. The rats were intervened by the daily administration of calycosin for 28 days after the con-
struction of the model.
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VEGF was induced by calycosin in a dose-dependent
manner. Compared with the DMSO group, a twofold
increase in VEGF expression was achieved by adminis-
tering 4 mg/kg of calycosin. A statistically significant
higher level of vegf expression with respect to the
DMSO group was observed with a calycosin dose as
low as 1 mg/kg (P = 0.01).
The expression level of β-actin was stable in all sam-
ples thus the expression level of the VEGF protein is
expressed as the fold-change relative to the β-actin ex-
pression level in the following results (Figure 5 A and
B). A nearly 3-fold increase in VEGF protein expres-
sion was observed in the DMSO group compared with
the sham control, and the expression level of the
VEGF protein was further increased in the entire caly-
cosin-treated group. Similar to the mRNA expression
results, the administration of 4 mg/kg of calycosin re-
sulted in the largest induction. VEGF protein expres-
sion increased by more than 2-fold compared with the
DMSO group at this dose, verifying the enhancement
of the angiogenesis signaling pathway by adding 4 mg/
kg calycosin. From the mRNA and protein expression
results for VEGF, calycosin was demonstrated to in-
duce an angiogenesis signal in the rat MI model. To in-
vestigate whether this induction functionally promotes
angiogenesis, the cellular responsewas further analyzed.
Effect of calycosin on CD31 expression
To evaluate angiogenesis in the myocardium, the num-
ber of cells expressing CD31 was analyzed by immuno-
histochemistry. CD31 is a specific antibody in the vas-
cular endodermis. Therefore, its expression level can be
used to indicate angiogenesis in the ischaemic myocar-
dium vascular. The surviving myocardium was dyed us-
ing standard immunohistochemical methods, and the
CD31-dyed microvasculature was counted (Figure 6).
It was observed that the number of CD31+ microvascu-
lar cells doubled in the 4 mg/kg calycosin-treated
group compared with the control, indicating angiogen-
ic promotion in the surviving myocardium (Figure 7).
This result coincides with the elevated ability for myo-
cardial regeneration in the calycosin-treated groups.
Thus, it is quite possible that due to its promotion of
angiogenesis in the ischaemic myocardium, calycosin
significantly improved the LVEF in the MI model.
Surprisingly, there was no increase in the number of
CD31 cells in the DMSO group compared with the
control in spite of its 2-fold higher mRNA level and
3-fold higher protein level for VEGF. This fact explains
the continuously decreased cardiac function of the
15
10
5
0
A B C D E F
Groups
Th
ed
iffe
ren
to
fV
EG
Fb
etw
een
48
th
ho
ur
an
d
28
th
day
(%
)
a
a
Figure 3 Decreasing of left ventricular ejection fractions from 48th h to 28th day in different groups
A-D: treated with 4, 2, 1 and 0.5 mg/kg of calycosin, respectively; E: treated with DMSO; F: sham-control. Four different doses of ca-
lycosin were intraperitoneally injected after the construction of the myocardial ischaemia model. DMSO: dimethyl sulfoxide. The
rats were intervened by the daily administration of calycosin for 28 days after the construction of the model. Data were expressed
as mean ± standard deviation (n = 9). Difference with aP < 0.05 was considered as statistically significant and were indicated with
an asterisk.
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Figure 4 Transcriptional expression of vascular endothelial growth factorin survived myocardium in different groups
A-D: treated with 4, 2, 1 and 0.5 mg/kg of calycosin, respectively; E: treated with DMSO; F: sham-control. Four different doses of ca-
lycosin were intraperitoneally injected after the construction of the myocardial ischaemia model. DMSO: dimethyl sulfoxide. The
rats were intervened by the daily administration of calycosin for 28 days after the construction of the model. Data were expressed
as mean ± standard deviation (n = 6). Difference with aP < 0.05 was considered as statistically significant and were indicated with
an asterisk.
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DMSO group and further demonstrates the necessity
for calycosin supplementation duringMI treatment.
DISCUSSION
In this study, the results of an echocardiography assay
indicate that the reduction of LVEF was prevented in
the calycosin-treated groups in the MI model. When
the dose increased to 4 mg/kg, cardiac function did not
further reduce from the 2nd to 28th day, suggesting its
effects in improving cardiac function during MI. As a
result, compared with the DMSO group, the LVEF val-
ue was 10% higher when 4 mg/kg of calycosin was ad-
ministered, which is better than current reported drugs
in MI models.
Calycosin is a phytoestrogen, and its function is report-
ed to involve the estrogen receptor and mitogen-activat-
ed protein kinase activation/modulation.9 Estrogen re-
duction results in risks for several diseases, especially
CVDs in postmenopausal women. However, estrogen
replacement therapy increases the risk of breast cancer,
stroke and thrombus-related diseases, as indicated by
recent epidemiology studies.15,16 These results have
prompted scientists to identify suitable phytoestrogens
to treat diseases that result from estrogen reduction. In
this study, calycosin exhibited functions similar to
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Figure 5 VEGF protein expression in survived myocardium in different groups
A: expression of β-actin in different groups; B: the relative expression level of VEGF. 1 to 4: treated with 4, 2, 1 and 0.5 mg/kg of ca-
lycosin, respectively; 5: treated with DMSO; 6: sham-control. DMSO: dimethyl sulfoxide; VEGF: vascular endothelial growth factor-
Four different doses of calycosin were intraperitoneally injected after the construction of the MI model. The rats were intervened
by the daily administration of calycosin for 28 days after the construction of the model. Data were expressed as mean ± standard
deviation (n = 6). Difference with aP < 0.05 was considered as statistically significant and were indicated with an asterisk.
1 2 3 4 5 6
β-actin
VEGF
A
B
A B C
D E F
Figure 6 CD31 expression in different groups (Immunohistochemical staining, ×400)
A to D: treated with 4, 2, 1 and 0.5 mg/kg of calycosin, respectively; E: treated with DMSO; F: sham-control. DMSO: dimethyl sulf-
oxide. The sample was dyed in diluted CD31 (1∶500), and standard immunohistochemical methods were employed. The
CD31-dyed microvasculature was detected and counted under a microscope. The purple dots indicated nucleus of the micro-vas-
cular and the brown dots indicated the CD31+ micro-vascular. Four different doses of calycosin were intraperitoneally injected af-
ter the construction of the myocardial ischaemia (MI) model. The rats were intervened by the daily administration of calycosin for
28 days after the construction of the model.
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those of estrogen, which substantially increased VEGF
expression at both the transcription and translation lev-
els in a dose-dependent manner. A similar induction of
VEGF expression by calycosin administration has also
been observed in zebra fish and HUVEC. It has been
demonstrated that calycosin can interact with estrogen
receptors and activate the mitogen-activated protein ki-
nase (MAPK) signaling pathway. In the MI model, the
vegf expression in the myocardium was enhanced by
the administration of calycosin, suggesting that a simi-
lar signal transduction event mediated the calyco-
sin-led effects. Although molecular responses to calyco-
sin were observed at doses as low as 1 mg/kg, only
4 mg/kg of calycosin resulted in an obvious improve-
ment in cardiac function and angiogenesis.
This dose-dependent calycosin effect is very informa-
tive for understanding myocardial regeneration in a MI
model. During MI, cells spontaneously respond to an
infarction at the molecular level. This phenomenon has
been reported as ischaemia-induced angiogenesis.10
Both the transcriptional and translational levels of
VEGF drastically increased in the myocardium due to
the MI-induced ischaemia. However, the substantially
increased expression of VEGF did not yield a detect-
able benefit on either cardiac function or the angiogen-
esis of the myocardial vascular. This phenomenon indi-
cates that angiogenesis activation requires the signal
strength to reach an excessively high level. Although
several drugs can induce the angiogenesis signal, the
strength is still below the threshold, resulting in little
improvement in cardiac function. Because functional
angiogenesis is difficult to activate without the proper
intervention, a high risk of myocardium death is un-
avoidable after MI treatment.
A similar nonfunctional induction of VEGF was also
observed when a lower dose of calycosin was adminis-
tered. The injection of 0.5 mg/kg of calycosin en-
hanced VEGF expression compared to the control;
however, an improvement in angiogenesis was only ob-
served when above 1 mg/kg of calycosin was adminis-
tered. Moreover, improved cardiac function was only
observed when 4 mg/kg of calycosin was used. At this
dose, VEGF expression was increased by 4- and 7-fold
at the mRNA and protein levels, respectively. Based on
this result, the injection of 4 mg/kg of calycosin is pro-
posed to be a suitable dose to activate angiogenesis and
to improve cardiac function in MI. In as short a time
as 28 days, a significant improvement in cardiac func-
tion and angiogenesis was observed compared to the
DMSO group. Because of the activation of angiogene-
sis, this improvement is expected to be even greater in
the long term; however, such an observation is still
pending.
In conclusion,calycosin improves the cardiac function
of MI rats through its induction of VEGF expres-
sion in the ischaemic myocardium and its accelera-
tion of angiogenesis. In addition, the CD31 + cell
number is also increased by calycosin treatment,
which further improves the reconstruction of the in-
farcted vasculature. The above results demonstrate
that calycosin is a potential candidate for myocardial
infarction treatment.
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